Lupin starts work on a new plant in India; FDA warning letters focus on contamination;

> Lupin, which already operates 11 manufacturing plants in India and Japan, has started construction of a new formulation facility in Mihan, Nagpur, India, which it expects to complete next year. Story

> Dalton Pharma Services in Canada has a contract to manufacture an antiviral agent developed by Defense Research and Development Canada (DRDC), for clinical trials in anticipation of getting the commercial contract later. Item

> An analysis by in-PharmaTechnologist of 2011 FDA warning letters found that a third of agency observations concerned the failure to have written procedures to prevent microbiological contamination. Report

> CRO Reaction Biology Corporation (RBC) has increased its epigenetic production capacity with a new facility in Malvern, PA. Article

> Industrial enzyme developer Codexis has gotten FDA approval for a new production process for manufacturing sitagliptin, the API in Merck's ($MRK) Januvia. More

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.